EU Approves First New Lung Fibrosis Drug in 10 Years

For the first time in more than ten years, doctors across Europe have a new weapon against diseases that slowly scar the lungs and steal people's ability to breathe.

The European Commission just approved Jascayd (nerandomilast) for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). These conditions cause lung scarring that makes breathing harder over time, leading to constant shortness of breath and coughing that robs people of their quality of life.

The approval brings hope to more than 500,000 Europeans and nine million people worldwide living with these progressive diseases. IPF has no known cause, while PPF can develop from other lung diseases or exposure to harmful substances.

Jascayd works by blocking an enzyme called phosphodiesterase 4B, which reduces inflammation and scarring in the lungs. The medication is taken orally, making it easier for patients to manage at home.

Two major clinical trials involving over 2,000 adults showed Jascayd significantly slowed lung function decline compared to placebo pills. The studies also suggested the treatment might reduce the risk of death, though more research is needed to confirm this finding.

The Bright Side

Unlike older pulmonary fibrosis treatments, Jascayd doesn't require regular liver monitoring tests. That means fewer doctor visits and blood draws for patients already managing a serious illness.

Dr. Marlies Wijsenbeek, a lung specialist at Erasmus MC University Medical Center in the Netherlands, highlighted another crucial advantage. Many patients stop earlier treatments because side effects become unbearable, but clinical trials showed people taking Jascayd stayed on their medication at similar rates to those taking placebo pills.

Common side effects include diarrhea, nausea, fatigue, and headache. While no medication is perfect, the tolerability profile means patients can actually stay on the treatment long enough for it to work.

Sue Farrington, president of the Federation of European Scleroderma Associations, said the approval offers renewed hope for families facing these progressive diseases. "When diagnosed with a progressive and irreversible lung condition like IPF or PPF, your greatest fear is running out of treatment options," she explained.

The medication previously received approval in the United States and Japan, and now European patients finally have access to the same breakthrough their counterparts overseas have been using.

For families watching their loved ones struggle to breathe, this approval means doctors can offer real hope instead of watching helplessly as lungs deteriorate.